Why is Abivax stock surging today?
Abivax shares rose nearly 6% in Paris after underwriters fully exercised a greenshoe option to buy 960,000 additional ADSs, raising total gross proceeds from its upsized public offering to $920m (€807m). The ADS offering priced at $125 on July 1. Jefferies upgraded Abivax to Buy, PT $158; company says cash runway extends into Q2 2029.
How this was made
The 30-second read
Why it matters
Full greenshoe exercise increases gross proceeds to $920M and is framed as extending cash runway into Q2 2029, alongside a Jefferies upgrade to Buy with a higher price target.
Market read
Traders can treat the full greenshoe exercise as a concrete, same-day catalyst that changes perceived funding risk and may drive short-term momentum/positioning in ABVX.
What to watch
The article doesn’t quantify net proceeds after fees, nor does it detail how the additional cash changes near-term milestones (e.g., specific trial readouts), which could limit sustained momentum.
Background
Abivax priced an upsized ADS offering on July 1, 2026, and the underwriters later announced full exercise of the overallotment (greenshoe) option.
Ticker impact
Abivax shares jumped ~6% after underwriters fully exercised a greenshoe, adding 960,000 ADSs and ~$920M gross proceeds.
Likely supports continued upside bias near-term, but follow-through may fade if the move is largely positioning around the offering mechanics.
The article ties the same-day surge directly to a newly disclosed financing step (full option exercise) plus an analyst upgrade and runway extension into 2029.
Market effects
Biopharma financing conditions/read-through: successful upsized offerings with full greenshoe can improve sentiment toward clinical-stage developers’ funding prospects.
Primarily Euronext Paris/European small/mid-cap sentiment via a single-name catalyst; limited index-level impact given CAC 40 near-flat.
Low—this is company-specific financing mechanics rather than a sector-wide macro/regulatory shift.
Counterpoint
The rally may be more about financing optics/positioning than incremental fundamental progress; dilution/financing overhang could reassert after the initial enthusiasm.
Key entities
- companyAbivax
Clinical-stage biopharma whose ADS price surged after underwriters fully exercised the greenshoe option, raising total gross proceeds to $920M.
- analyst_firmJefferies
Upgraded Abivax to Buy from Hold and raised its price target to $158 from $108.
